Deep Vein Thrombosis
Pipeline by Development Stage
Deep Vein Thrombosis is a ~$24.6B indication-level market dominated by two factor Xa inhibitors in a mature, consolidated therapeutic landscape.
Key Trends
- Duopoly market: ELIQUIS and XARELTO control ~100% of attributed revenue
- Legacy anticoagulants (FRAGMIN, LOVENOX) facing loss of exclusivity with minimal modern spending
- Limited pipeline innovation: 77 trials mostly in Phase 3/Phase 4, suggesting incremental rather than transformative development
Career Verdict
DVT is a stable but low-growth niche—suitable for specialists seeking deep expertise in anticoagulation, but not ideal for those seeking rapid advancement in high-momentum disease areas.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 74% | Launch | Stable | 15.0yr |
| 2 | XARELTO (rivaroxaban) | Johnson & Johnson | $6.3B | 26% | Peak | Stable | 8.2yr |
| 3 | FRAGMIN (dalteparin sodium) | Pfizer | $2M | 0% | Loss of Exclusivity Approaching | Declining |
Drug Class Breakdown
Dominant, mature class
Legacy, minimal revenue
Career Outlook
StableDVT is a mature, consolidated market offering stable career paths in commercial execution, manufacturing scale, and regulatory affairs—but limited upside in R&D or business development. The duopoly (ELIQUIS/XARELTO) and thin pipeline suggest that growth will come from market share gains and geographic expansion rather than innovation. Best suited for professionals seeking specialization in anticoagulation or those building expertise in mature-market management.
Breaking In
Enter via Commercial or Manufacturing rotational programs at BMS or J&J; build deep anticoagulation knowledge and payer negotiation skills, as margin defense and managed-care excellence will define success in this market through LOE.
For Experienced Professionals
If you have >5 years in anticoagulation, pursue Regulatory/Pharmacovigilance or Market Access leadership roles—these carry premium compensation ($356K+ for Clinical Ops) and insulate against pipeline risk as LOE approaches.
In-Demand Skills
Best For
Hiring Landscape
DVT-focused hiring is concentrated in Commercial (685 roles, $266K avg) and Manufacturing (489 roles, $182K avg), reflecting mature market dynamics where sales execution and supply-chain efficiency dominate. Johnson & Johnson leads with 1,605 DVT-area jobs, followed by Sanofi (853) and BMS (600). Clinical Operations (232 roles, $356K avg) offers highest compensation, indicating demand for regulatory and safety expertise.
By Department
Commercial and manufacturing roles dominate; Clinical Operations offers premium compensation for those with regulatory or pharmacovigilance expertise in anticoagulation.
Competitive Landscape
20 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 22 trials with date data
Clinical Trials (22)
Total enrollment: 6,885 patients across 22 trials
Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome
Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System
Innohep® in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis
The D-KAF (Dalteparin in Knee-to-Ankle Fracture) Trial
Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial
A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries
Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
The STOP CLOT Pilot Study: Study of Low Molecular Weight Heparin in High Risk Cesarean Section
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
Odiparcil For The Prevention Of Venous Thromboembolism
Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study
Personalized Medicine Decision-Making in a Virtual Clinical Setting
ClotTriever® Thrombectomy System Use-Result Survey in Japan
Determining the Validity of ThinkSono Guidance for Ultrasound Image Acquisition and Remote Detection
Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting
BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
Thromboprophylaxis for Patients Undergoing Surgical Resection for Colon Cancer
3 Screen Electronic Alert
Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism
Understanding Risk Factors Involved in Developing a Second Blood Clot.
Related Jobs in Cardiovascular
Senior Therapeutic Area Specialist, Cardiovascular Specialty - Wilmington, DE
Associate Director, US Medical Learning, Cardiovascular (CV)
Senior Therapeutic Area Specialist, Cardiovascular Community - Upper Manhattan E
Senior Manager, Global Medical Immunology & Cardiovascular, Medical Communications (Rheumatology)
Senior Therapeutic Area Specialist, Cardiovascular Specialty - Spring Hill, FL
Director, Global HEOR, Cardiovascular
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.